文献速递临床试验与 GCP

腹腔镜袖状胃切除术与Roux-en-Y胃旁路术5年减重效果比较:SLEEVEPASS随机临床试验

Effect of Laparoscopic Sleeve Gastrectomy vs Laparoscopic Roux-en-Y Gastric Bypass on Weight Loss at 5 Years Among Patients With Morbid Obesity: The SLEEVEPASS Randomized Clinical Trial.
PubMed 文献 · JAMA · 2018-01-01

SLEEVEPASS多中心开放标签随机等效性试验纳入240例病态肥胖患者,随机接受腹腔镜袖状胃切除术(n=121)或Roux-en-Y胃旁路术(n=119),随访5年。5年时估计平均多余体重减少百分比在袖状胃切除组为49%(95%CI 45%-52%),胃旁路组为57%(95%CI 53%-61%),差异8.2个百分点(95%CI 3.2%-13.2%),胃旁路组更高,未达到预设等效标准。

要点

  • 5年多余体重减少百分比:袖状胃切除组49% vs 胃旁路组57%,差异8.2个百分点(95%CI 3.2%-13.2%),未达等效标准。
  • 2型糖尿病完全或部分缓解:袖状胃切除组37%(15/41) vs 胃旁路组45%(18/40),P > .99。
  • 高血压药物停用:袖状胃切除组29%(20/68) vs 胃旁路组51%(37/73),P = .02。

核心结论

  • 在病态肥胖患者中,腹腔镜袖状胃切除术与腹腔镜Roux-en-Y胃旁路术相比,5年多余体重减少百分比未达到等效标准。
  • 胃旁路术相比袖状胃切除术在5年时多余体重减少百分比更高,但基于预设等效界值,差异无统计学意义。

研究设计与样本

  • SLEEVEPASS为多中心、多术者、开放标签、随机临床等效性试验,2008年3月至2010年6月在芬兰开展。
  • 纳入240例18至60岁病态肥胖患者,随机分配至袖状胃切除术(n=121)或Roux-en-Y胃旁路术(n=119),随访5年。
  • 主要终点为多余体重减少百分比,预设等效界值为-9%至+9%多余体重减少。

主要发现

  • 5年估计平均多余体重减少百分比:袖状胃切除组49%(95%CI 45%-52%) vs 胃旁路组57%(95%CI 53%-61%),差异8.2个百分点(95%CI 3.2%-13.2%),胃旁路组更高。
  • 2型糖尿病完全或部分缓解:袖状胃切除组37%(15/41) vs 胃旁路组45%(18/40),P > .99。
  • 血脂异常药物停用:袖状胃切除组47%(14/30) vs 胃旁路组60%(24/40),P = .15。
  • 高血压药物停用:袖状胃切除组29%(20/68) vs 胃旁路组51%(37/73),P = .02。
  • 5年总体并发症发生率:袖状胃切除组19%(23例) vs 胃旁路组26%(31例),P = .19;两组生活质量无统计学显著差异(P = .85),无治疗相关死亡。

关键数值与推荐

  • 主要终点等效界值:多余体重减少差异-9%至+9%。
  • 5年多余体重减少百分比:袖状胃切除组49%(95%CI 45%-52%) vs 胃旁路组57%(95%CI 53%-61%),差异8.2个百分点(95%CI 3.2%-13.2%),未满足等效标准。

临床怎么用

  • 对于病态肥胖患者,袖状胃切除术与胃旁路术在5年减重效果上未达等效,胃旁路术多余体重减少百分比更高但差异无统计学意义。
  • 高血压药物停用在胃旁路组更常见(51% vs 29%,P = .02),2型糖尿病缓解和血脂异常药物停用两组无显著差异。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Laparoscopic sleeve gastrectomy for treatment of morbid obesity has increased substantially despite the lack of long-term results compared with laparoscopic Roux-en-Y gastric bypass. OBJECTIVE: To determine whether laparoscopic sleeve gastrectomy and laparoscopic Roux-en-Y gastric bypass are equivalent for weight loss at 5 years in patients with morbid obesity. DESIGN, SETTING, AND PARTICIPANTS: The Sleeve vs Bypass (SLEEVEPASS) multicenter, multisurgeon, open-label, randomized clinical equivalence trial was conducted from March 2008 until June 2010 in Finland. The trial enrolled 240 morbidly obese patients aged 18 to 60 years, who were randomly assigned to sleeve gastrectomy or gastric bypass with a 5-year follow-up period (last follow-up, October 14, 2015). INTERVENTIONS: Laparoscopic sleeve gastrectomy (n = 121) or laparoscopic Roux-en-Y gastric bypass (n = 119). MAIN OUTCOMES AND MEASURES: The primary end point was weight loss evaluated by percentage excess weight loss. Prespecified equivalence margins for the clinical significance of weight loss differences between gastric bypass and sleeve gastrectomy were -9% to +9% excess weight loss. Secondary end points included resolution of comorbidities, improvement of quality of life (QOL), all adverse events (overall morbidity), and mortality. RESULTS: Among 240 patients randomized (mean age, 48 [SD, 9] years; mean baseline body mass index, 45.9, [SD, 6.0]; 69.6% women), 80.4% completed the 5-year follow-up. At baseline, 42.1% had type 2 diabetes, 34.6% dyslipidemia, and 70.8% hypertension. The estimated mean percentage excess weight loss at 5 years was 49% (95% CI, 45%-52%) after sleeve gastrectomy and 57% (95% CI, 53%-61%) after gastric bypass (difference, 8.2 percentage units [95% CI, 3.2%-13.2%], higher in the gastric bypass group) and did not meet criteria for equivalence. Complete or partial remission of type 2 diabetes was seen in 37% (n = 15/41) after sleeve gastrectomy and in 45% (n = 18/40) after gastric bypass (P > .99). Medication for dyslipidemia was discontinued in 47% (n = 14/30) after sleeve gastrectomy and 60% (n = 24/40) after gastric bypass (P = .15) and for hypertension in 29% (n = 20/68) and 51% (n = 37/73) (P = .02), respectively. There was no statistically significant difference in QOL between groups (P = .85) and no treatment-related mortality. At 5 years the overall morbidity rate was 19% (n = 23) for sleeve gastrectomy and 26% (n = 31) for gastric bypass (P = .19). CONCLUSIONS AND RELEVANCE: Among patients with morbid obesity, use of laparoscopic sleeve gastrectomy compared with use of laparoscopic Roux-en-Y gastric bypass did not meet criteria for equivalence in terms of percentage excess weight loss at 5 years. Although gastric bypass compared with sleeve gastrectomy was associated with greater percentage excess weight loss at 5 years, the difference was not statistically significant, based on the prespecified equivalence margins. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00793143.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Salminen P, Helmiö M, Ovaska J, et al. Effect of Laparoscopic Sleeve Gastrectomy vs Laparoscopic Roux-en-Y Gastric Bypass on Weight Loss at 5 Years Among Patients With Morbid Obesity: The SLEEVEPASS Randomized Clinical Trial. JAMA. 2018. PMID: 29340676. doi:10.1001/jama.2017.20313

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。